Quantitative measurement of soluble cytokeratin fragments in tissue cytosol of 599 node negative breast cancer patients: A prognostic marker possibly associated with apoptosis

Breast Cancer Research and Treatment

Volumn 59, Issue 3, 2000, Pages 211-221

  Gion, Massimo ^a   Boracchi, Patrizia ^d   Dittadi, Ruggero ^a   Biganzoli, Elia ^b   Peloso, Lucia ^a   Gatti, Carlo ^a   Paccagnella, Adriano ^a   Rosabian, Alberto ^d   Vinante, Orazio ^c   Meo, Sabrina ^a  

^a Ospedale Civile Dolo   (Italy)

^b Istituto di Statistica Medica e Biometria   (Italy)

^c Boldrini Hospital   (Italy)

^d Ospedale Boldrini ^*

Author keywords

Apoptosis; Breast cancer; Continuous variables statistical analysis; Cytokeratins; Multiple correspondence analysis; Prognosis; Tissue cytosol; Tissue polypeptide antigen (TPA)

Indexed keywords

CASPASE; CYTOKERATIN; CYTOKERATIN 18; CYTOKERATIN 19 FRAGMENT; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P53; STEROID RECEPTOR; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKER;

ADJUVANT THERAPY; ADULT; AGE; AGED; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER STAGING; CYTOSOL; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOCHEMISTRY; IMMUNORADIOMETRIC ASSAY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; QUANTITATIVE ASSAY; RECURRENCE RISK;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; APOPTOSIS; BREAST NEOPLASMS; CYTOSOL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; ITALY; KERATINS; MIDDLE AGED; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SOLUBILITY; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034052417     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006318112776     Document Type: Article

References (48)

1. 1. Silvestrini R, Daidone MG, Luisi A, Boracchi P, Mezzetti M, Di Fronzo G, Andreola S, Salvation B, Veronesi U: Biologic and clinicopathologic factors as indicators of specific relapse types in node-negative breast cancer. J Clin Oncol 13: 697-704, 1995
2. 2. Goldhirsch A, Click JH, Gelber RD, Seen HJ: Meeting highlights: International consensus panel on the treatment of primary breast cancer. J Natl Cancer I 90: 1601, 1998
3. 3. Gasparini G: Prognostic variables in node-negative and node-positive breast cancer - editorial. Breast Cancer Res Treat 52: 321-331, 1998
4. 4. Ellis LM, Walker RA, Gasparini G: Is determination of angiogenic activity in human tumours clinically useful? Eur J Cancer 34(5): 609-618, 1998
5. 5. Gasparini G, Toi M, Gion M, Verderio P, Dittadi R, Hanatani M, Matsubara I, Vinante O, Bonoldi E, Boracchi P, Gatti C, Suzuki H, Tominaga T: Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer I 89: 139-147, 1997
6. 6. Toi M, Gion M, Biganzoli E, Dittadi R, Boracchi P, Miceli R, Meli S, Mori K, Tominaga T, Gasparini G: Co-determination of the angiogenic factors thymidine phosphorylase and vascular endothelial growth factor in node-negative breast cancer: prognostic implications. Angiogenesis 1: 71-83, 1997
7. 7. Dittadi R, Brazzale A, Pappagallo G, Salbe C, Nascimben O, Rosabian A, Gion M: ErbB2 assay in breast cancer: possibly improved clinical information using a quantitative method. Anticancer Res 17: 1245-1248, 1997
8. 8. Koscielny S, Terrier P. Spielmann M, Delarue JC: Prognostic importance of low c-erbB2 expression in breast tumors. J Natl Cancer I 90(9): 712, 1998
9. 9. Coradini D, Biganzoli E, Boracchi P, Bombardieri E, Seregni E, De Palo G, Martelli G, Di Fronzo G: Effect of steroid receptors, pS2 and cathepsin D on the outcome elderly breast cancer patients: an exploratory investigation. Int J Cancer 79(4): 305-311, 1998
10. 10. Dittadi R, Biganzoli E, Boracchi P, Salbe C, Mione R, Gatti C, Gion M: Impact of steroid receptors, pS2 and cathepsin D on the outcome of N + postmenopausal breast cancer patients treated with tamoxifen. Int J Biol Mark 13(1): 30-41, 1998
11. 11. Biganzoli E, Boracchi P, Daidone MG, Gion M, Marubini E: Flexible modelling in survival analysis. Structuring biological complexity from the information provided by tumor markers. Int J Biol Mark 13: 107-123, 1998
12. 12. Osborne C: Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat 51: 227-238, 1998
13. 13. Hupperets PS, Volovics E, Schouten LJ, Jager JJ, Schouten HC, Hillen HF, Blijham GH: The prognostic significance of steroid receptor activity in tumor tissue of patients with primary breast cancer. Am J Clin Oncol 20(6): 546-551, 1997
14. 14. Ozbun MA, Butel JS: Tumor suppressor p53 mutations and breast cancer: a critical analysis. Adv Cancer Res 66: 71-141, 1995
15. 15. Barbareschi M: Prognostic value of the immunohistochemical expression of p53 in breast carcinomas. Immunohistochemistry 4(2): 106-116, 1996
16. 16. Bates S, Vousden KH: Mechanisms of p53-mediated apoptosis. Cell Mol life Sci 55(1): 28-37, 1999
17. 17. Hockenbery D: Defining apoptosis. Am J Pathol 146(1): 16, 1995
18. 18. Ellis RE, Yuan J, Horvitz HR: Mechanism and function of cell death. Ann Rev Cell Biol 7: 663-698, 1991
19. 19. Sanders EJ: Methods for detecting apoptotic cells in tissues. Histol Histopathol 12(4): 1169-1177, 1997
20. 20. Ku NO, Liao J, Omary MB: Apoptosis generates stable fragments of human type I keratins. J Biol Chem 272(52): 33197-33203, 1997
21. 21. Dittadi R, Coradini D, Meo S, Pirronello E, Daidone MG, Gion M: Tissue polypeptide antigen as a putative indicator of apoptosis. Clin Chem 44(9): 2002-2003, 1998
22. 22. Gion M, Mione R, Gatti C, Dittadi R, Leon AE, Castiglioni C, Nascimben O, Bruscagnin G: Tissue polypeptide antigen in tumor cytosol: a new prognostic indicator in primary breast cancer. Breast Cancer Res Treat 17: 15-21, 1990
23. 23. Veronesi U, Salvadori B: Breast conservation is a safe method in patients with small cancer of the breast. Long-term results ot three randomised trials on 1,973 patients. Eur J Cancer 31: 1574-1579, 1995
24. 24. Gion M, Dittadi R, Leon AE, Bruscagnin G, Pelizzola D, Giovannini G, Giganti M, Messeri G, Quercioli M, Flamini E, Riccobon A, Bozzetti C, Benecchi M, De Lena M, Paradiso A, Ruggeri G, Luisi P, Piffanelli A: Comparison between single saturating dose ligand binding assay and enzyme immunoassay for low-salt extractable oestrogen and progesterone receptors in breast cancer: a multicenter study. Eur J Cancer 27(8): 996-1002, 1991
25. 25. EORTC Breast Cancer Cooperative Group: Revision of the standards for the assessment of hormone receptors in human breast cancer: report of the second EORTC Workshop. Eur J Cancer 16: 1513-1515, 1980
26. 26. Dittadi R, Brazzale A, Mione R, Di Fresco S, Gatti C, Vinante O, Bassan F, Nascimben O, Gion M: Quantitative chemiluminescent immunoassay of p53: prognostic significance in 220 node-negative breast cancer tissue. Anticancer Res 17: 4691-4696, 1997
27. 27. Greenacre MJ: Correspondence Analysis in practice. Academic Press, London, 1996
28. 28. Benzecrì JP: Sur le calcul des taux d'inertie dans l'analyse d'un questionnaire. Le Cahiers de l'Analyse des Données 4: 377-383, 1979
29. 29. Lebart L, Morineau A, Piron M: Statistique exploratoire multidimensionelle. Dunod, Paris, 1995
30. 30. Grambsch P, Therneau T: Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81: 515-526, 1994
31. 31. Durrleman S, Simon R: Flexible regression models with cubic splines. Stat Med 8: 551-561, 1989
32. 32. Thorpe SM: Estrogen and progesterone receptor determinations in breast cancer. Tecnology, biology and clinical significance. Acta Oncol 27(1): 1-19, 1988
33. 33. Wilking N, Rutqvist E, Nordenskjöld B, Skoog L: Steroid receptor levels in breast cancer. Relationship with age and menopausal status. Acta Oncol 28: 807-810, 1989
34. 34. Silvestrini R, Benini E, Daidone MG, Veneroni S, Boracchi P, Cappelletti V, Di Fronzo G, Veronesi U: p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Nat Cancer Inst 85: 965-970, 1993
35. 35. Sauerbrei W, Schumacher M: A bootstrap resampling procedure for model building: application to the Cox regression model. Stat Med 11: 2093-2109, 1992
36. 36. Harrel FE, Lee KL, Mark DB: Tutorial in biostatistics multivariable prognostic model: issues in developing models, evaluating assumption and adequacy, and measuring and reducing errors. Stat Med 15: 361-387, 1996
37. 37. Altman DG, De Stavola BL, Love SB. Stepniewska KA: Review of survival analyses published in cancer journals. Brit J Cancer 72: 551-558, 1995
38. 38. Altman DG, Lausen B, Sauerbrei W, Schumaker M: Danger of using 'optimal' cutpoints in the evaluation of prognostic factors. J Natl Cancer I 86: 829-835, 1994
39. 39. Gion M, Mione R, Pappagallo GL, Gatti C, Nascimben O, Brandes A, Vinante O, Bruscagnin G: Tissue polypeptide antigen in breast cancer cytosol. A new effective prognostic indicator. Eur J Cancer 29A(1): 66-69, 1993
40. 40. Gion M, Mione R, Dittadi R, Fasan S, Pallini A, Bruscagnin G: Carcinoembryonic antigen, ferritin and tissue polypeptide antigen in serum and tissue. Relationship with the receptor content in breast carcinoma. Cancer 57(5): 917-922, 1986
41. 41. Gion M, Mione R, Becciolini A, Balzi M, Correale M, Piffanelly A, Giovannini G, Saccani Jotti G, Fontanesi M: Relationship between cytosol TPS, TPA and cell proliferation. Int J Biol Mark 9(2): 109-114, 1994
42. 42. Gion M, Mione R, Barioli P, Sartorello P, Capitanio G: Tissue polypeptide antigen and tissue polypeptide specific antigen in primary breast cancer. Evaluation in serum and tumour tissue. Eur J Clin Chem Clin Biochem 32: 779-787, 1994
43. 43. Neville AM, Bettelheim R, Gelber RD, Save-Soderbergt J, Davis BW, Reed R, Torhorst J, Golouh R, Peterson HF, Price KN, Isley M, Rudenstam CM, Collins J, Castiglione M, Senn HJ, Goldhrisch A: Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. J Clin Oncol 10(5): 696-705, 1992
44. 44. Davis BW, Gelber RD, Goldhirsch A, Hartmann WH, Locher GW, Reed R, Golouh R, Save-Soderbergh J, Holloway L, Russel I, Rudenstam M: Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Cancer 58: 2662-2670, 1986
45. 45. Caulìn C, Salvesen GS, Oshima RG: Caspase cleavage of keratin 18 and reorganisation of intermediate filaments during epithelial cell apoptosis. J Cell Biol 136(6): 1379-1394, 1997
46. 46. Mellerik DM, Osborn M, Weber K: On the nature of serological tissue polypeptide antigen (TPA): monoclonal keratin 8, 18, 19 antibodies react differently with TPA prepared from human serum. Oncogene 5: 100-117, 1990
47. 47. Cohen GM: Caspases: the executioners of apoptosis. Biochem J 326: 1-16, 1997
48. 48. Leers MPG, Kölgen W, Björklund V, Bergman T, Tribbick G, Persson B, Björklund P, Ramaekers FCS, Björklund B, Nap M, Jörnvall H, Schutte B: Immunocytochemical detection and mapping of a cytokeratin 18 neco-epitope exposed during early apoptosis. J Pathol, 1999 (in press)